Vasculitis & polymyalgia rheumatica
Immunosuppressive Therapies in Ear, Nose, and Throat Involvement in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Results From a Multicenter Retrospective Cohort Study
Main finding · ENT activity at last visitResult — go to the resultAdjusted odds ratio 0.59 95% CI 0.33–1.06Authors' conclusion
In this cohort, CYC and RTX therapy had similar therapeutic effects on ENT symptoms in AAV.
Study context
- Population
- Patients with antibody-associated vasculitis (AAV) treated January 2010–April 2020 at 2 Dutch hospitals; Ear, nose, and throat (ENT) involvement defined as ≥ 1 ENT symptom by BVAS3 and/or saddle nose deformity209 (65.3%) with ENT involvement
- Participants
- 320 patients
- Exposure
- CYC vs rituximab (RTX)
- CYCn = 137
- RTXn = 55reference
- Outcome
- ENT activity at last visit
- Follow-up
- Last visit
Methodological detailsmulticentre, logistic regression
- Multicentre
- Logistic regression
Main finding
As reported in the abstract
Adjusted odds ratio
0.59
95% CI 0.33–1.06
P = 0.08
CYCvs RTX
aOR 0.59 (95% CI 0.33–1.06); P = 0.08
Observational data: associations, not effects.
Further findings
Persistent ENT symptoms despite immunosuppressive therapy (patients with ENT involvement)
- ENT symptoms at relapse
- 50% (n = 77)
- ENT activity at last visit
- 29.1% (n = 59)
Factors associated with ENT activity at last follow-up
- Lower age at disease onset and female sex independently associated with ENT activity
Original publication
Immunosuppressive Therapies in Ear, Nose, and Throat Involvement in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Results From a Multicenter Retrospective Cohort Study. J Rheumatol. Published 15 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →